普罗布考对脑梗塞进展期患者APTT、纤维蛋白原及血液流变学的影响

Effect of Probucol on APTT, fibrinogen and hemorheology in patients with progressive cerebral infarction

摘要:

摘要：目的  探讨普罗布考治疗对脑梗塞进展期患者活化部分凝血活酶时间（APTT）、纤维蛋白原及血液流变学的影响，为普罗布考治疗脑梗塞的临床应用提供依据。方法  选取2014年1月-2015年1月该院神经内科收治的80例脑梗塞进展期患者为研究对象，随机分为研究组和对照组，每组40例，对照组采取常规药物治疗，研究组在对照组基础上加用普罗布考，比较两组患者治疗前后的APTT、纤维蛋白原及血液流变学的变化。结果  研究组的疗效与对照组比较，差异统计学意义（P <0.05）。研究组患者治疗后APTT较治疗前延长，且治疗后30 d时间较治疗后15 d延长。研究组患者治疗后APTT与对照组比较，差异有统计学意义（P <0.05）。研究组患者治疗后纤维蛋白原水平较治疗前降低，且治疗后30 d水平低于治疗后15 d；研究组患者治疗后的纤维蛋白原水平与对照组比较，差异有统计学意义（P <0.05）。研究组患者治疗后的血浆黏度、全血高切黏度及全血低切黏度较治疗前均降低，且治疗后30 d较治疗后15 d降低；研究组患者治疗后血浆黏度、全血高切黏度及全血低切黏度与对照组比较，差异有统计学意义（P <0.05）。结论  普罗布考治疗脑梗塞进展期患者疗效显著，能够延长APTT，降低纤维蛋白原水平，降低血浆黏度、全血高切黏度及全血低切黏度，值得推广应用。

Abstract:

Abstract: Objective To explore the effect of Probucol on activated partial thromboplastin time (APTT), fibrinogen and hemorheology in patients with progressive cerebral infarction. Methods Eighty cases with progressive cerebral infarction from January 2014 to January 2015 in our hospital were chosen as research objects. They were randomly divided into study group and control group with 40 cases in each group. The control group was treated with simple routine drugs, the study group had the same treatment plus Probucol. APTT, fibrinogen and hemorheology of the patients were evaluated before and after treatment and compared between the two groups. Results The total effective rate of the study group was significantly higher than that of the control group (P < 0.05). In the study group APTT was prolonged after treatment. APTT on the 30th day after treatment was longer than that on the 15th day after treatment. After treatment, APTT of the study group was significantly longer than that of the control group (P < 0.05).  The fibrinogen level of the study group was lower after treatment than before treatment, and the fibrinogen level on the 30th day after treatment was lower than that on the 15th day after treatment. The fibrinogen level after treatment in the study group was significantly lower than that in the control group (P < 0.05). After treatment, the plasma viscosity, whole blood high-shear viscosity and whole blood low-shear viscosity of the study group decreased, which were lower on the 30th day after treatment than on the 15th day after treatment. The plasma viscosity, whole blood high-shear viscosity and whole blood low-shear viscosity of the study group were significantly reduced compared to the control group with statistical difference (P < 0.05). Conclusions The curative effect of Probucol on patients with cerebral infarction is significant. Probucol can significantly prolong APTT and lower fibrinogen level, reduce blood viscosity, whole blood high-shear viscosity and low-shear viscosity, and is worthy of clinical application.